Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07307664 · ClinicalTrials.gov registry record · NA
Increasing Germline Genetic Testing for Patients With Cancer
A NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study, sponsored by Josh Peterson.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 10
- Study locations
NCT07307664 is a NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study that is actively recruiting participants, run by Josh Peterson. The registered enrollment target is 1,000 participants. The trial reports 10 study locations across 9 states.
The verdict
NCT07307664, a NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study, is actively recruiting participants, sponsored by Josh Peterson.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.
Conditions Studied
Interventions
- BEHAVIORAL Implementation strategies
Study Locations (10)
North Carolina
- Durham VA Medical Center - Durham
- Salisbury VA Health Care System - Salisbury
California
- VA Greater Los Angeles Healthcare System - Los Angeles
Florida
- Orlando VA Medical Center - Orlando
Georgia
- Atlanta VA Medical Center - Decatur
Illinois
- Northwestern Medicine - Chicago
Indiana
- Indiana University School of Medicine - Indianapolis
Pennsylvania
- Geisinger - Danville
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2030-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07307664
The ClinicalTrials.gov registry entry for NCT07307664 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Josh Peterson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hereditary Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Implementation strategies is the first listed.
NCT07307664 reports 10 study locations spanning 9 distinct geographic areas - top geographies include North Carolina, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07307664 about?
NCT07307664 is a clinical study titled "Increasing Germline Genetic Testing for Patients With Cancer". Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test orderin...
What is the current status of trial NCT07307664?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2026-01-30. Estimated completion is 2030-01-01.
What conditions does trial NCT07307664 study?
This clinical trial studies the following conditions: Hereditary Pancreatic Cancer, Conditions or Focus of Study, Hereditary Breast Cancer, Hereditary Colorectal Cancer.
What interventions are being tested in trial NCT07307664?
The interventions under investigation include: Implementation strategies (BEHAVIORAL).
Who is sponsoring clinical trial NCT07307664?
This trial is sponsored by Josh Peterson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07307664 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Hereditary Pancreatic Cancer
All registered trials for this condition
Conditions or Focus of Study
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.